Enzo Biochem Past Earnings Performance
Past criteria checks 0/6
Enzo Biochem's earnings have been declining at an average annual rate of -14.7%, while the Healthcare industry saw earnings growing at 6% annually. Revenues have been declining at an average rate of 28.2% per year.
Key information
-14.7%
Earnings growth rate
-13.6%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | -28.2% |
| Return on equity | -15.1% |
| Net Margin | -23.8% |
| Last Earnings Update | 31 Oct 2024 |
Recent past performance updates
Recent updates
Enzo Biochem, Inc.'s (NYSE:ENZ) 28% Share Price Plunge Could Signal Some Risk
Feb 13
Enzo Biochem, Inc.'s (NYSE:ENZ) 33% Share Price Plunge Could Signal Some Risk
Dec 18Will Enzo Biochem (NYSE:ENZ) Spend Its Cash Wisely?
Nov 19Enzo Biochem: Is This Time Finally Different?
Jul 17Enzo Biochem: Cleaned Up And Cash-Rich But Unloved
Oct 26Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?
May 18Is Enzo Biochem (NYSE:ENZ) A Risky Investment?
Jan 03Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M
Dec 12Enzo Biochem appoints Patricia Eckert as interim CFO
Oct 20Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M
Oct 14Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?
Oct 04Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale
Jun 27Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?
May 03Is Enzo Biochem (NYSE:ENZ) A Risky Investment?
Dec 17Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?
Aug 24Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?
Mar 01Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?
Feb 03If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%
Jan 08
Enzo Biochem nabs expanded EUA nod for testing of COVID samples
Jan 04Enzo Biochem: Betting On The Activists Now
Dec 16Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay
Dec 13Revenue & Expenses Breakdown
How Enzo Biochem makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Oct 24 | 30 | -7 | 22 | 2 |
| 31 Jul 24 | 32 | -10 | 24 | 3 |
| 30 Apr 24 | 33 | -18 | 28 | 3 |
| 31 Jan 24 | 33 | -23 | 34 | 4 |
| 31 Oct 23 | 32 | -25 | 34 | 4 |
| 31 Jul 23 | 31 | -25 | 32 | 4 |
| 30 Apr 23 | -32 | -27 | 10 | 2 |
| 31 Jan 23 | -13 | -24 | 15 | 3 |
| 31 Oct 22 | 13 | -23 | 23 | 2 |
| 31 Jul 22 | 33 | -20 | 29 | 2 |
| 30 Apr 22 | 112 | -7 | 54 | 4 |
| 31 Jan 22 | 118 | 0 | 52 | 3 |
| 31 Oct 21 | 116 | 5 | 51 | 3 |
| 31 Jul 21 | 118 | 8 | 50 | 3 |
| 30 Apr 21 | 112 | 1 | 48 | 4 |
| 31 Jan 21 | 97 | -11 | 48 | 4 |
| 31 Oct 20 | 84 | -21 | 48 | 4 |
| 31 Jul 20 | 76 | -29 | 50 | 4 |
| 30 Apr 20 | 77 | -31 | 50 | 4 |
| 31 Jan 20 | 80 | 2 | 48 | 4 |
| 31 Oct 19 | 80 | 1 | 48 | 4 |
| 31 Jul 19 | 81 | 2 | 47 | 3 |
| 30 Apr 19 | 83 | 2 | 49 | 3 |
| 31 Jan 19 | 89 | -23 | 50 | 3 |
| 31 Oct 18 | 95 | -16 | 51 | 3 |
| 31 Jul 18 | 101 | -10 | 50 | 3 |
| 30 Apr 18 | 106 | -4 | 49 | 3 |
| 31 Jan 18 | 108 | -2 | 48 | 3 |
| 31 Oct 17 | 108 | -2 | 47 | 3 |
| 31 Jul 17 | 105 | -3 | 46 | 3 |
| 30 Apr 17 | 106 | 34 | 49 | 3 |
| 31 Jan 17 | 106 | 31 | 50 | 3 |
| 31 Oct 16 | 104 | 39 | 52 | 3 |
| 31 Jul 16 | 103 | 45 | 52 | 4 |
| 30 Apr 16 | 102 | 18 | 53 | 4 |
| 31 Jan 16 | 99 | 17 | 52 | 3 |
| 31 Oct 15 | 98 | 6 | 51 | 3 |
| 31 Jul 15 | 98 | -2 | 52 | 3 |
| 30 Apr 15 | 97 | -14 | 52 | 3 |
| 31 Jan 15 | 97 | -11 | 52 | 3 |
| 31 Oct 14 | 97 | -11 | 52 | 3 |
| 31 Jul 14 | 96 | -10 | 52 | 3 |
| 30 Apr 14 | 94 | -10 | 50 | 3 |
Quality Earnings: ENZ is currently unprofitable.
Growing Profit Margin: ENZ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ENZ is unprofitable, and losses have increased over the past 5 years at a rate of 14.7% per year.
Accelerating Growth: Unable to compare ENZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ENZ is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (20%).
Return on Equity
High ROE: ENZ has a negative Return on Equity (-15.13%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 09:59 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enzo Biochem, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bradley Berning | Craig-Hallum Capital Group LLC |
| Reni Benjamin | Rodman & Renshaw, LLC |
| Jack Wallace | Sidoti & Company, LLC |